Skip to main content
Tech.euFundingExplorerBeta

Signals

Funding-only, explainable estimates from the data — not predictions, and not investment advice. Each score shows its base rate and the factors behind it.

Base rates (this dataset): a round is followed by another 37% of the time · 11.6% of companies with 2+ rounds have exited. · snapshot as of 2026-06-19
Methodology →
FundingDeal volume flat but capital up 25% — average round size has jumpedAI read →

Tech.eu Heat 50

Healthtech · top 50
#CompanyStageLast roundTimingRaise nextHeat
1Isomorphic Labs
Healthtech · UK
Series B2026-05just raised · ▲37100
2Biorce
Healthtech · Spain
Series A2026-02just raised · ▲3298
3FoRx Therapeutics
Healthtech · Switzerland
Series A2025-12just raised · ▲3296
4Centauri
Healthtech · UK
Series A2026-02just raised · ▲3294
5IMU Biosciences
Healthtech · UK
Other2026-06just raised · ▲2193
6Aerska
Healthtech · Ireland
Series A2026-02just raised · ▲3293
7Ingenix
Healthtech · Poland
Seed2026-06just raised · ▲3192
8tacalyx
Healthtech · Germany
Seed2026-04just raised · ▲3192
9Ona Therapeutics
Healthtech · Spain
Series B2026-06just raised · ▲3491
10Recare Solutions
Healthtech · Germany
Other2026-01just raised · ▲2191
11Oura Health
Healthtech · Finland
Series D+2025-10in window · ▲6588
12Tubulis Technologies
Healthtech · Germany
Series C2025-10in window · ▲6288
13Uromems
Healthtech · France
Growth/Late2026-05just raised · ▲2788
14Vitestro
Healthtech · Netherlands
Series B2026-03just raised · ▲3487
15EnteroBiotix
Healthtech · UK
Other2026-05just raised · ▲2387
16Owlstone Medical
Healthtech · UK
Grant2025-10in window · ▲5786
17OpenUp
Healthtech · Netherlands
Other2026-03just raised · ▲2186
18SamanTree Medical
Healthtech · Switzerland
Other2026-01just raised · ▲2186
19Flinn
Healthtech · Austria
Other2026-02just raised · ▲2185
20Alvotech
Healthtech · Iceland
Debt2026-01in window · ▲5584
21Evaro
Healthtech · UK
Series A2026-01just raised · ▲3284
22Exciva
Healthtech · Germany
Series B2026-01just raised · ▲3483
23Hypervision Surgical
Healthtech · UK
Series A2026-04just raised · ▲3283
24Generare
Healthtech · France
Series A2026-04just raised · ▲3283
25nyra health
Healthtech · Austria
Series A2026-02just raised · ▲3283
26Axmed
Healthtech · Switzerland
Grant2026-02just raised · ▲3383
27Imperagen
Healthtech · UK
Seed2026-05just raised · ▲3182
28Oviva
Healthtech · UK
Series D+2026-01just raised · ▲3881
29NVision Imaging
Healthtech · Germany
Series B2026-05just raised · ▲3481
30Optics11
Healthtech · Netherlands
Debt2026-01in window · ▲5581
31Luminate Medical
Healthtech · Ireland
Series A2026-01just raised · ▲3281
32AMSilk
Healthtech · Germany
Other2025-09in window · ▲3780
33Lucis
Healthtech · France
Series A2026-05just raised · ▲3280
34Tucuvi
Healthtech · Spain
Series A2026-01just raised · ▲3280
35MyC
Healthtech · France
Other2026-02just raised · ▲2180
36Bioliberty
Healthtech · UK
Other2026-03just raised · ▲2380
37Anocca
Healthtech · Sweden
Other2025-08in window · ▲4079
38Berlin Heals Holding
Healthtech · Germany
Other2026-02just raised · ▲2379
39GlycanAge
Healthtech · UK
Other2025-12just raised · ▲2179
40Avenue Biosciences
Healthtech · Finland
Seed2026-01just raised · ▲3179
41Qida
Healthtech · Spain
Other2025-11in window · ▲3778
42Xyall
Healthtech · Netherlands
Other2026-02just raised · ▲2378
43Psyomics
Healthtech · UK
Seed2025-10in window · ▲5978
44RAYDIAX
Healthtech · Germany
Other2026-03just raised · ▲2178
45Gate2Brain
Healthtech · Spain
Other2026-06just raised · ▲2378
46Leyden Labs
Healthtech · Netherlands
Other2025-10in window · ▲3777
47NRG Therapeutics
Healthtech · UK
Series B2025-09in window · ▲5977
48Storm Therapeutics
Healthtech · UK
Series C2026-04just raised · ▲4077
49Phagos
Healthtech · France
Series A2025-10in window · ▲5477
50Cellply
Healthtech · Italy
Other2026-05just raised · ▲2177

Most likely to raise next

next-round likelihood

Exit candidates

exit likelihood · 2+ rounds

Scores are model estimates, not facts: a base rate computed from this dataset, adjusted by transparent funding-only factors (timing vs cohort gap, round-size momentum, backer re-investment, firm characteristics). No per-company “unicorn” probability is published. In a back-test (cut-off 30 June 2023, 18-month horizon), companies the model placed in their typical raise window went on to raise again about 1.8× as often as the average tracked company (~14% vs ~8%), while companies flagged dormant raised under 1% of the time. Estimates, not predictions.